Phase 1Completed

Trial of INI-4001 in Patients With Advanced Solid Tumours

An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours

Sponsor
Inimmune Corporation (Industry)
Enrollment
10 enrolled
Conditions
Advanced Solid Tumor
Interventions
INI-4001; Nivolumab; Pembrolizumab; Cemiplimab; Avelumab; Atezolizumab; Durvalumab
Ages
adults, older adults
Registry
NCT06302426

Full record on ClinicalTrials.gov

From the registry

Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.

Primary outcomes

  • Incidence of dose-limiting toxicities (DLTs) during Cycle 1 to determine the maximum tolerated dose of INI-4001 Monotherapy

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered